• EZ Cap Cy5 Firefly Luciferase mRNA Workflow

  2026-09-10

  Use one mRNA to separate delivery, intracellular trafficking, and translation with Cy5 fluorescence plus Firefly luciferase output. This practical workflow supports transfection optimization, translation efficiency assays, and in vivo bioluminescence imaging while highlighting limitations when reporter data are translated to therapeutic mRNA studies.

• BV6: Practical Design for Reliable Cell-Death Assays

  2026-09-10

  A scenario-driven guide to using BV6 as an IAP antagonist in viability, apoptosis, radiosensitization, and combination-treatment studies. It explains how SKU B4653 supports more interpretable workflows through defined solubility, storage, and mechanism-of-action information.

• mTORC1 Oscillations Coordinate Cell-Cycle Progression

  2026-09-09

  Joshi et al. show that mTORC1 activity oscillates across the cell cycle, reaching its lowest levels in mitosis and G1 and its highest levels in S and G2. The study links this pattern to interphase progression, Chk1/Wee1-dependent mitotic entry, and phase-specific sensitivity to autophagy induction, providing a framework for designing more temporally resolved cell-cycle experiments.

• α-Bungarotoxin: Nicotinic Receptor Blockade

  2026-09-09

  α-Bungarotoxin is a high-affinity α7 nicotinic acetylcholine receptor antagonist used to create a defined nicotinic receptor blockade in cellular and tissue experiments. In a 2026 preeclampsia-like rat study, α-bungarotoxin helped test whether pyridostigmine effects depended on α7 nAChR signaling.

• PF-562271 HCl for FAK/Pyk2 Cancer Research

  2026-09-08

  PF-562271 HCl gives cancer researchers a reversible, ATP-competitive way to interrogate FAK/Pyk2 signaling across adhesion, migration, tumor growth, and microenvironment assays. This workflow-focused guide connects phospho-FAK readouts with radiotherapy and checkpoint-blockade models while clearly separating established evidence from testable extensions.

• ARCA EGFP mRNA (5-moUTP): Workflow Strategy

  2026-09-08

  A mechanism-driven guide to using ARCA EGFP mRNA (5-moUTP) as a fluorescence-based transfection control, with practical guidance on assay design, storage, translational relevance, and experimental interpretation.

• Deferasirox Fe3+ Chelate: From PK to Assay Design

  2026-09-07

  Deferasirox Fe3+ chelate connects the clinical pharmacology of Exjade with practical assay design for iron overload treatment research. This article explains how chemical form, solubility, controls, and translational context should shape beta-thalassemia iron chelation experiments.

• Sulfo-Cy3 NHS Ester for Vascular Assays

  2026-09-07

  Sulfo-Cy3 NHS Ester is a hydrophilic fluorescent dye for designing aqueous protein-tracking assays around the AIBP–LRP2–HDL–miR-223 pathway. This guide connects its NHS-amine chemistry and spectral properties to rigorous vascular remodeling experiments while distinguishing particle uptake from downstream signaling.

• ac4C–Gm26917 Control of FGSC Translation

  2026-09-05

  This study identifies an ac4C–Gm26917–EEF1A1–Rpl10 pathway that connects lncRNA modification with ribosome-associated translation in female germline stem cells. By integrating acRIP-seq, RIC-seq, and ribosome profiling, it shows that ac4C supports Gm26917 stability and spatial recruitment of Rpl10 mRNA, thereby preserving protein synthesis and stem-cell maintenance.

• D-N-Acetylgalactosamine: Protocol & QC Guide

  2026-09-04

  This guide provides practical handling, solvent, storage, and quality-control instructions for D-N-Acetylgalactosamine (SKU B7904) in glycoprotein and neurological research workflows. It is suitable for controlled aqueous or compatible DMSO preparations, but not for ethanol-based protocols or long-term storage of prepared solutions.

• DiscoveryProbe Bioactive Compound Library Plus for TSA

  2026-09-04

  Use the DiscoveryProbe Bioactive Compound Library Plus to connect thermal stability shifts with pathway-level biology, from bacterial sensor ligand discovery to cellular validation. Its 5,072 pre-dissolved compounds support efficient triage, while orthogonal binding and phenotype assays help separate actionable ligands from assay artifacts.

• G007-LK Tankyrase 1/2 Inhibitor Workflow

  2026-09-03

  G007-LK provides a selective way to connect tankyrase activity with AXIN stabilization, β-catenin turnover, and Hippo-pathway responses. This practical guide covers pathway-focused assays, APC-mutant colorectal models, hepatocellular carcinoma extensions, and troubleshooting strategies for reproducible results.

• DRD2 Variants and Pathogenic G Protein Signaling

  2026-09-03

  A 2024 Biochemical Pharmacology study compared two pathogenic DRD2 variants associated with hyperkinetic movement disorders and identified stronger constitutive and agonist-driven G protein signaling as a likely explanation for the greater severity of Met374Arg disease. By combining cellular pharmacology, second-messenger analysis, receptor stability testing, and molecular dynamics simulations, the work connects variant-specific receptor behavior with clinical differences while illustrating how orthogonal assays can strengthen mechanistic interpretation.

• Covalent HPV-16 E6 Inhibitors Restore p53

  2026-09-02

  The reference study identifies a genotype-defined vulnerability in HPV-16–positive cancer by covalently and irreversibly targeting a cysteine near the E6AP-binding interface of the viral E6 oncoprotein. Inhibition restored p53 activity, triggered apoptosis or senescence, and suppressed cervical and oropharyngeal tumor xenografts, providing a mechanistic framework for targeted HPV-associated cancer research.

• BRD4–RAC1 Co-Targeting in Breast Cancer

  2026-09-02

  The reference study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy that suppresses breast cancer growth, migration, stemness, and xenograft tumorigenesis. Its mechanistic contribution is to connect this treatment response with disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1, providing a framework for studying chromatin regulation alongside oncogenic signaling.

8029 records 1/536 page Next 12345 下5页 Last page